Genome & Company Announces Conversion of 1.28M Preferred Shares to Common Shares, Leading to 2.5% Dilution
Genome & Company received conversion requests for 1,280,870 preferred shares into common shares on July 15 and 20, 2026, with the new shares to be listed on August 10, 2026.
The conversion increases common shares from 50,875,015 to 52,155,885, diluting existing common shareholders by approximately 2.5 percent.
The preferred shares were originally issued in July 2025 via a third-party allotment, and this conversion follows the predetermined schedule.
[AI Summary]Genome & Company's conversion of preferred shares into common shares results in moderate dilution of 2.5 percent for existing shareholders. The conversion is a routine step following the original issuance, with no new capital raised and no material governance change. Investors should monitor the dilution impact on earnings per share.
KOSDAQ Filing Information
Other Management Matters (Voluntary Disclosure) (Conversion Request of Convertible Preferred Shares into Common Shares)